Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.63 |
| ▸ | MEN1 | O00255 | 9/20 | 0.63 |
| ▸ | HTT | P42858 | 7/20 | 0.63 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 10/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124723 | 0.84 | RAB9A (0.70) | KMT2AMEN1HTTRAB9ANPC1 | |
| SCHEMBL4111928 | 0.84 | MAPT (0.68) | KMT2AMEN1HTTRAB9ANPC1 | |
| SCHEMBL4106282 | 0.83 | MAPT (0.61) | KMT2AMEN1HTTRAB9ANPC1 | |
| SCHEMBL4118510 | 0.83 | KMT2A (0.72) | KMT2AMEN1HTTRAB9ANPC1 | |
| SCHEMBL4118526 | 0.83 | MAPT (0.66) | KMT2AMEN1HTTRAB9ANPC1 | |
| SCHEMBL2872598 | 0.81 | EPHX2 (0.69) | KMT2AMEN1HTTRAB9ANPC1 | |
| SCHEMBL4124838 | 0.80 | IDO1 (0.58) | KMT2AMEN1HTTRAB9ANPC1 | |
| SCHEMBL4124133 | 0.80 | MAPT (0.59) | KMT2AMEN1HTTLMNASTING1 | |
| SCHEMBL4116853 | 0.80 | MAPT (0.62) | KMT2AMEN1HTTRAB9ALMNA | |
| SCHEMBL4115667 | 0.79 | KMT2A (0.60) | KMT2AMEN1HTTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | KMT2A 2807/4885MEN1 3273/4885HTT 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.